English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 18 April 2019, 20:00 HKT/SGT
Share:
    

Source: ReShape Lifesciences Inc.
ReShape Lifesciences Announces Distribution in Australia

SAN CLEMENTE, CA & MELBOURNE, AU, Apr 18, 2019 - (ACN Newswire) - ReShape Lifesciences™, a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announces that as of April 1, 2019, the company was selling its LAP-BAND® product in the Australian market through a relationship with Satori Healthcare. Satori Healthcare is a medical device distributor focused on the Australian bariatric market.

The founder of Satori Healthcare has over 20 years of experience in the medical device industry, including 6 years of direct responsibility for LAP-BAND while it was owned by Allergan and Apollo Endosurgery respectively. Concurrent with this relationship, ReShape Lifesciences has fully taken over all distribution of the LAP-BAND product in Australia from Apollo Endosurgery, Inc. and will subsequently be recognizing revenue from sales of the product in Australia.

Over 120,000 LAP-BAND procedures have taken place in Australia since the product was launched in the country, making Australia one of the largest worldwide markets for LAP-BAND outside of the U.S. Australia was one of the early adopters of the LAP-BAND technology and has produced some of the strongest data and research on the product. According to the OECD 2017 Obesity Update, based on self-reported data, 27.9% of the Australian adult population are obese, the fifth highest obesity rate of any developed country.

About ReShape Lifesciences Inc

ReShape Lifesciences™ (OTCQB: RSLS) is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Investor Contact:
Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
+1-949-429-6680 x106
[email protected]

SOURCE: ReShape Lifesciences Inc.

Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
A Glimpse into BYD's Blade Battery Factory in Chongqing  
June 6, 2020 10:00 HKT/SGT
84000 Launches an Animation Video to Preserve Buddhist Texts  
June 5, 2020 21:00 HKT/SGT
TOYOTA GAZOO Racing to Make Virtual Le Mans Debut  
June 5, 2020 16:34 HKT/SGT
Toyota Mobility Foundation to Expand Provision of Connected and Sanitized Mobility Services to support Healthcare in Indonesia in Support of the Fight against COVID-19  
June 5, 2020 16:22 HKT/SGT
Six Companies Establish R&D Joint Venture for Commercial Vehicle Fuel Cell Systems for the Creation of a Hydrogen-based Society in China  
June 5, 2020 16:01 HKT/SGT
HTSC joins hands with WWF to support 13 local teams in protecting biodiversity in the Yangtze River region  
June 5, 2020 15:38 HKT/SGT
MINY Makes Crypto Mining Affordable For Everyone  
June 5, 2020 13:00 HKT/SGT
JCB Enables Cross-Border QR-Code Payments with FIS  
June 5, 2020 09:00 HKT/SGT
Singapore's LABMED shipped over 20 million masks to meet global demand  
June 4, 2020 21:00 HKT/SGT
WARC Awards 2020 - Effective Use of Brand Purpose winners announced   
June 4, 2020 16:00 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575